Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OAX Equities |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2021-02-15 08:05:06
Oslo, Norway (15 February 2021) - In connection with the voluntary offer by
Lesaffre being announced this morning, NattoPharma hereby announces the
following key financials for Q4 2020 and FY 2020:
Q4 2020 revenue and adj. EBITDA amounts to NOK 62.3m and NOK 14.4m, respectively
(adj. EBITDA margin of 23.1%).
FY 2020 revenue and adj. EBITDA amounts to NOK 214.5m and NOK 37.3m,
respectively (adj. EBITDA margin of 17.4%).
NattoPharma will release the Q4 2020 report on 17 February 2021. The
presentation will be held as earlier communicated at 10:00 AM CET that same day.
However, there will be no Q&A as earlier indicated.
For more information, please contact:
Robert Schrama
CFO, NattoPharma
E-mail: robert.schrama@nattopharma.com